Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Sikander Ailawadhi, MD, Meghna Ailawadhi, MD, Srilekha Bodepudi, Mays F Abdulazeez, BMSC, Zan Tahir Shareef, Ashna Grover, Maria J Fernandez, Winston Tan, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 411.

https://doi.org/10.1182/blood-2019-125722

Published: 2019

Journal Articles

Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Hishaam Bhimji, BSP, Dean Eurich, PhD, Kerry Mansell, PharmD, MBA, Holly Mansell, PharmD

Blood (2019) 134 (Supplement_1): 2126.

https://doi.org/10.1182/blood-2019-122751

Published: 2019

Journal Articles

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact

Radhika Jhaveri, PharmD, Vaishali Sanchorawala, MD, John Mark Sloan, MD, Adam Lerner, MD, Shayna Sarosiek, Bhavesh Shah, RPh

Blood (2019) 134 (Supplement_1): 4758.

https://doi.org/10.1182/blood-2019-128992

Published: 2019

Journal Articles

Realized and Projected Cost Savings from the Introduction of Generic Imatinib, with Minimal Additional Savings to Payers through Formulary Management

Lisa Bloudek, John Brokars, MS, Campbell David, PharmD, MS, Dinara Makenbaeva, MD MBA

Blood (2018) 132 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2018-99-111966

Published: 2018

Journal Articles

Standard Processing of Apheresis Products for HSCT Provides Significant Cost Savings over Automated Processing without Impact on Time or Product Quality

Lauren Bongo, MLS, Ravi Bhatia, MD, Lawrence S. Lamb, Jr., PhD

Blood (2018) 132 (Supplement 1): 5693.

https://doi.org/10.1182/blood-2018-99-119295

Published: 2018

Journal Articles

Cost-Effective Use of White Blood Cell Growth Factors in the Veterans Administration

Kevin Knopf, MD, William Hrureshky, Bryan Love, Leann Norris, Charles L. Bennett, MD PhD

Blood (2018) 132 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2018-99-119724

Published: 2018

Journal Articles

Reducing Unnecessary Coagulation Testing in Outpatients (REDUCTION): A Quality Improvement Project

Fatima Khadadah, MBBS, Aziz Jiwajee, Hina Chaudhry, BSc, Paula D. James, MD, Rosane Nisenbaum, PhD, Rajesh Girdhari, MD, Curtis Handford, MD, Jonathan Hunchuck, Michelle Sholzberg, MDM, MSc, FRCPC

Blood (2018) 132 (Supplement 1): 4703.

https://doi.org/10.1182/blood-2018-99-113694

Published: 2018

Journal Articles

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Ali McBride, PharmD,MS, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham, PhD RN, Sanjeev Balu

Blood (2017) 130 (Supplement 1): 3380.

https://doi.org/10.1182/blood.V130.Suppl_1.3380.3380

Published: 2017

Journal Articles

Reduced 2: Reducing Unnecessary Coagulation Testing in the Emergency Department, Stage 2

Nicola Goldberg, MD, Hina Chaudhry, Alun Ackery, MD FRCPC, Michelle Sholzberg, MDM, MSc, FRCPC

Blood (2017) 130 (Supplement 1): 5581.

https://doi.org/10.1182/blood.V130.Suppl_1.5581.5581

Published: 2017

Journal Articles

Projected Cost Savings of a Plasmic Score-Based Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura

Vivek A Upadhyay, MD, Benjamin Geisler, MD, Lova Sun, MD, Christopher P. Stowell, MD PhD, Lynne Uhl, MD, Richard Kaufman, MD, Robert Makar, MD PhD, Pavan Bendapudi, MD

Blood (2017) 130 (Supplement 1): 3742.

https://doi.org/10.1182/blood.V130.Suppl_1.3742.3742

Published: 2017

Journal Articles

Program Expansion of a Day Hospital Dedicated to Manage Sickle Cell Pain

Jin Han, PharmD, PhD, Laura Kavoliunaite, APN, Santosh L. Saraf, MD, Shivi Jain, MD, Johara Hassan, MD, Lewis L Hsu, MD PhD, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Michel Gowhari, DO

Blood (2017) 130 (Supplement 1): 4664.

https://doi.org/10.1182/blood.V130.Suppl_1.4664.4664

Published: 2017

Journal Articles

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Gili Kenet, MD, Abiola Oladapo, PhD BPharm, Josh Epstein, PhD, Thompson Christin, PhD, Aaron Novack, Diane J. Nugent, MD

Blood (2017) 130 (Supplement 1): 4632.

https://doi.org/10.1182/blood.V130.Suppl_1.4632.4632

Published: 2017

Journal Articles

A Value-Based Approach to Optimizing Peripheral Blood Progenitor Cell (PBPC) Mobilization and Collection for Autologus Hematopoietc Cell Transplantation (AHCT)

Srinivasa Reddy Sanikommu, MD, Emily S Reese, PhD MPH, Carlos Lee, Jiaxian He, MS, Daisuke Goto, PhD, Omotayo O. Fasan, MBBS, Kimberly Ward, Saad Z Usmani, MD, Nilanjan Ghosh, MD PhD, Manisha Bhutani, MD, Ryan Jacobs, MD, Peter M. Voorhees, MD, Sarah Lestrange, MS, Jigar Trivedi, MSc, PharmD, Carol Farhangfar, PhD, James T Symanowski, PhD, Edward A Copelan, MD, Belinda Rene Avalos, MD

Blood (2017) 130 (Supplement 1): 4717.

https://doi.org/10.1182/blood.V130.Suppl_1.4717.4717

Published: 2017

Journal Articles

Home Administration of Subcutaneous Rituximab Is Safe and Associated with Significant Cost Saving: A Single Center Experience

Alice Wolfromm, MD, Benedicte Mittaine, MD, Nicolas Gandrille, MD, Julie Dallemagne, MD, Richard Delarue, MD

Blood (2017) 130 (Supplement 1): 4676.

https://doi.org/10.1182/blood.V130.Suppl_1.4676.4676

Published: 2017

Journal Articles

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States

Ahmed Aljabri, Yvonne Huckleberry, Jason H. Karnes, Mahdi Gharaibeh, Hussam I. Kutbi, Yuval Raz, Seongseok Yun, Ivo Abraham, Brian Erstad

Blood (2016) 128 (26): 3043–3051.

https://doi.org/10.1182/blood-2016-07-728030

Published: 2016

Journal Articles

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Maria Luci, MD, Maria Aquila Santoro, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2016) 128 (22): 1269.

https://doi.org/10.1182/blood.V128.22.1269.1269

Published: 2016

Journal Articles

Using Chargemaster Data to Understand Childhood Leukemia Costs

Michael R. Sprehe, MD MPH, Ruth Johnson, R.Ph.

Blood (2016) 128 (22): 5938.

https://doi.org/10.1182/blood.V128.22.5938.5938

Published: 2016

Journal Articles

Analyzing the Impact of Implementing a Systems-Based Hematologist into the Healthcare Delivery System at an Academic Medical Center

Charles S Greenberg, MD, Caroline Dupre Vaughn, RN, Alice Boylan, MD, Jerry E Squires, MDPhD, Sharon DeGrace, RN,MN, John Lazarchick, MD, Adrian Reuben, MBBS,FRCP,FACG, Alan C. Finley, MD, Joseph Mazur, PharmD,BCPS,BCNSP

Blood (2015) 126 (23): 4467.

https://doi.org/10.1182/blood.V126.23.4467.4467

Published: 2015

Journal Articles

Content, Utilization and Impact of a Hematology e-Consultation Service

Karima Khamisa, MDFRCPC, Adam Fogel, BSc, Clare Liddy, MD MSc, CCFP, FCFP, Erin Keely, MD FRCPC, Amir Afkham, BEng

Blood (2015) 126 (23): 42.

https://doi.org/10.1182/blood.V126.23.42.42

Published: 2015

Journal Articles

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Timothy E. Kubal, MD MBA, Christopher Rodriguez Salamanca, PA, Julio C Chavez, MD, Bijal D. Shah, MD, Rami S. Komrokji, MD, Viet Q. Ho, PharmD, RPh, BCOP, Jeffrey E Lancet, MD

Blood (2015) 126 (23): 5604.

https://doi.org/10.1182/blood.V126.23.5604.5604

Published: 2015

NARROW

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact

Realized and Projected Cost Savings from the Introduction of Generic Imatinib, with Minimal Additional Savings to Payers through Formulary Management

Standard Processing of Apheresis Products for HSCT Provides Significant Cost Savings over Automated Processing without Impact on Time or Product Quality

Cost-Effective Use of White Blood Cell Growth Factors in the Veterans Administration

Reducing Unnecessary Coagulation Testing in Outpatients (REDUCTION): A Quality Improvement Project

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Reduced 2: Reducing Unnecessary Coagulation Testing in the Emergency Department, Stage 2

Projected Cost Savings of a Plasmic Score-Based Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura

Program Expansion of a Day Hospital Dedicated to Manage Sickle Cell Pain

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

A Value-Based Approach to Optimizing Peripheral Blood Progenitor Cell (PBPC) Mobilization and Collection for Autologus Hematopoietc Cell Transplantation (AHCT)

Home Administration of Subcutaneous Rituximab Is Safe and Associated with Significant Cost Saving: A Single Center Experience

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Using Chargemaster Data to Understand Childhood Leukemia Costs

Analyzing the Impact of Implementing a Systems-Based Hematologist into the Healthcare Delivery System at an Academic Medical Center

Content, Utilization and Impact of a Hematology e-Consultation Service

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only